News

Under the terms of the agreement, AstraZeneca has received a payment of $178m from Cheplapharm. The Company may also receive future sales-contingent payments of up to $61m. The

Upon completion of the merger, the merged company would operate under the name Tarveda Therapeutics, Inc. and trade on the Nasdaq Stock Market LLC under the ticker symbol

HemaCare has expertise in the customisation of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development. HemaCare provides a range of human

The two phase 3 trials for Jardiance called EMPERIAL-Reduced and EMPERIAL-Preserved were carried out in adults with chronic heart failure with reduced and preserved ejection fraction, respectively. In

The study showed adding Tecentriq (atezolizumab) to Cotellic (cobimetinib) and Zelboraf (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and

TED is a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement that can

The company has unveiled the topline results from its global phase 111 Luster-1 and Luster-2 studies evaluating the efficacy and safety of the investigational oral, once-daily, DP2 receptor

These new data, from a primary analysis of the FeDeriCa study, will be presented in a spotlight session at 07.00 CST today at the 2019 San Antonio Breast

It is estimated that about 8 percent of patients with DMD have this mutation. “The FDA recognizes the urgent need for new medical treatments for serious neurological disorders